title: Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two affinity states of the CCK-B receptor on transfected CHO cells.
abstract: To improve our knowledge of the bioactive conformation of CCK-B antagonists, we have developed a new series of constrained dipeptoids whose synthesis and biochemical properties are reported here. These compounds, of general structure N alpha-[(2-adamantyloxy)carbonyl]-alpha-methyltryptophanyl-(4 -X)-proline, were designed by introducing a cyclization in the structure of the previously described CCK-B/peptoid antagonist RB 210, N-[N-[(2-adamantyloxy)carbonyl]-DL-alpha-methyltryptophanyl] -N-(2-phenylethyl)glycine (Blommaert et al. J. Med. Chem. 1993, 36, 2868-2877), by means of a five-membered ring. Structure-affinity relationship studies showed that an R configuration of Trp-C alpha and a cis configuration of the pyrrolidine substituents were favorable for receptor recognition. The most potent compounds of this new series had similar affinities for the CCK-B receptor as RB 210 and proved to be far more efficient in inhibiting inositol phosphate production in CHO cells stably transfected with rat brain CCK-B receptor, with IC50 values approaching those of the commonly used antagonists L-365,260 and PD-134,308. Moreover, binding studies performed using transfected CHO cells showed that two affinity states of the CCK-B receptor can be discriminated by some of these compounds which also have different biological profiles and are therefore highly interesting tools for the biochemical and pharmacological characterization of CCK-B receptor heterogeneity.
authors.affiliation: Département de Pharmacochimie Moléculaire et Structurale, U266 INSERM-URA D1500, CNRS, UFR des Sciences Pharmaceutiques et Biologiques, Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Bellier
authors.forename: I
authors.initials: I
authors.lastname: McCort-Tranchepain
authors.forename: B
authors.initials: B
authors.lastname: Ducos
authors.forename: S
authors.initials: S
authors.lastname: Danascimento
authors.forename: H
authors.initials: H
authors.lastname: Meudal
authors.forename: F
authors.initials: F
authors.lastname: Noble
authors.forename: C
authors.initials: C
authors.lastname: Garbay
authors.forename: B P
authors.initials: BP
authors.lastname: Roques
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology; D000818:Animals; D016466:CHO Cells / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D006224:Cricetinae; D004151:Dipeptides / Q000138:chemical synthesis* / Q000494:pharmacology*; D006168:Guinea Pigs; D007700:Kinetics; D009682:Magnetic Resonance Spectroscopy; D034444:Peptoids; D011392:Proline / Q000031:analogs & derivatives; D011487:Protein Conformation; D051381:Rats; D043886:Receptor, Cholecystokinin A; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D013329:Structure-Activity Relationship; D013379:Substrate Specificity; D014162:Transfection
chemical_list: D004151:Dipeptides; D034444:Peptoids; D043886:Receptor, Cholecystokinin A; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; D011392:Proline; D000218:Adamantane